Exacerbations leading to ED visits · children with asthma
1 finding from 1 review
Mean exacerbations requiring a course of oral corticosteroids · children with asthma
1 finding from 1 review
Exacerbations leading to ED visits · patients with children with asthma
1 finding from 1 review
Mean exacerbations requiring a course of oral corticosteroids · patients with children with asthma
1 finding from 1 review
Exacerbations needing hospitalisation · people with asthma
Formoterol showed no clear difference in patients with an exacerbation requiring hospitalisation compared with short‐acting beta2‐agonist (moderate certainty).
1 finding from 1 review
Exacerbations requiring oral corticosteroids ‐ adults · people with asthma
Formoterol probably leads to lower patients with an exacerbation requiring a course of oral… compared with short‐acting beta2‐agonist (moderate certainty).
1 finding from 1 review
Fatal serious adverse events · people with asthma
Formoterol showed no clear difference in fatal serious adverse events (all‐cause) compared with short‐acting beta2‐agonist (low certainty).
1 finding from 1 review
Patients with a serious adverse event (all cause) · people with asthma
Formoterol showed no clear difference in patients with a serious adverse event (all cause) compared with short‐acting beta2‐agonist (low certainty).
1 finding from 1 review
Asthma‐related serious adverse event · people with asthma
Formoterol showed no clear difference in patients with a serious adverse event (asthma related) compared with short‐acting beta2‐agonist (low certainty).
1 finding from 1 review
Withdrawals due to any reason · people with asthma
Formoterol may leads to higher withdrawals (any reason) compared with short‐acting beta2‐agonist (low certainty).
1 finding from 1 review
Intervention not reported
Number of subjects who had one or more exacerbations over the study period in adults ( · Adults and children with asthma
The intervention showed no clear difference in number of subjects who had one or more exacerbations over the study… (moderate certainty).
1 finding from 1 review
Intervention not reported
Number of subjects who had one or more exacerbations over the study period in children and adolescents ( · Adults and children with asthma
The intervention showed no clear difference in number of subjects who had one or more exacerbations over the study… (moderate certainty).
1 finding from 1 review
Intervention not reported
Number of exacerbations per 52 weeks in adults ( · Adults and children with asthma
1 finding from 1 review
Intervention not reported
Number of exacerbations per 52 weeks in children and adolescents ( · Adults and children with asthma
1 finding from 1 review
Intervention not reported
ICS dose at final visit in adults ( · Adults and children with asthma
1 finding from 1 review
Intervention not reported
ICS dose at final visit in children and adolescents ( · Adults and children with asthma
1 finding from 1 review
Intervention not reported
Number of participants with increased cough · patients with prolonged non‐specific cough in children
The intervention showed no clear difference in number of participants with increased cough (moderate certainty).
1 finding from 1 review
All‐cause mortality ‐ adults and adolescents · patients with chronic asthma
Regular salmeterol showed no clear difference in all‐cause mortality ‐ adults and adolescents compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause non‐fatal serious adverse events ‐ adults and adolescents · patients with chronic asthma
Regular salmeterol showed no clear difference in all‐cause non‐fatal serious adverse events ‐ adults and adolescents compared with regular salbutamol (moderate certainty).
1 finding from 1 review
All‐cause non‐fatal serious adverse events ‐ children · patients with chronic asthma
Regular salmeterol showed no clear difference in all‐cause non‐fatal serious adverse events ‐ children compared with regular salbutamol (moderate certainty).
1 finding from 1 review